Jaap Verweij


Ontology type: schema:Person     


Person Info

NAME

Jaap

SURNAME

Verweij

Publications in SciGraph latest 50 shown

  • 2015-12 miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway in MOLECULAR CANCER
  • 2014-05 Determining the optimal dose in the development of anticancer agents in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2012-07 Effects of CYP Induction by Rifampicin on Tamoxifen Exposure in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 2011-05 Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2011-01 Effects of methimazole on the elimination of irinotecan in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2010-11-18 Early Clinical Trials with Cytotoxic Agents in PRINCIPLES OF ANTICANCER DRUG DEVELOPMENT
  • 2010-09 Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours in BRITISH JOURNAL OF CANCER
  • 2009-07 Application of prolonged microdialysis sampling in carboplatin-treated cancer patients in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2009-02 Pharmacogenetic Pathway Analysis of Docetaxel Elimination in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 2009-02 The Price of Success: Cost‐Effectiveness of Molecularly Targeted Agents in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 2008-07 Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 2008-02 Drug Insight: gastrointestinal stromal tumors (GIST)—the solid tumor model for cancer-specific treatment in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2008-01 A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours in BRITISH JOURNAL OF CANCER
  • 2008 How to Define Treatment Success or Failure if Tumors Do Not Shrink in MOLECULAR TARGETING IN ONCOLOGY
  • 2007-09 Influence of ketoconazole on the fecal and urinary disposition of docetaxel in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2007-03 Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2006-08 Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 2006-02 PII‐20 in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 2005-02 A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2005-02 Evaluation of body‐surface area based dosing of cisplatin in patients with extreme BSA values in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 2004-10 Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours in BRITISH JOURNAL OF CANCER
  • 2004-04 Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor in BRITISH JOURNAL OF CANCER
  • 2004 Targeted therapy: Ready for prime time? in TARGETING TREATMENT OF SOFT TISSUE SARCOMAS
  • 2003-11 Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 2003-04 Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients in BRITISH JOURNAL OF CANCER
  • 2002-07 Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38 in BRITISH JOURNAL OF CANCER
  • 2002-01 Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer in BRITISH JOURNAL OF CANCER
  • 2001-10 Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy in BRITISH JOURNAL OF CANCER
  • 2001-10 Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer in BRITISH JOURNAL OF CANCER
  • 2001-05 Introduction: Recent Topics in the Clinical Pharmacology of Taxanes that Might Change Future Perspectives in INVESTIGATIONAL NEW DRUGS
  • 2001-05 Role of Formulation Vehicles in Taxane Pharmacology in INVESTIGATIONAL NEW DRUGS
  • 2001-04 Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2001-03 Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane in BREAST CANCER RESEARCH AND TREATMENT
  • 2000-08 Development of Multidrug-Resistance Convertors: Sense or Nonsense? in INVESTIGATIONAL NEW DRUGS
  • 2000-07 A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours in BRITISH JOURNAL OF CANCER
  • 2000-06 Clinical Pharmacokinetics of 2′-Deoxy-2′-Methylidenecytidine (DMDC), a Deoxycytidine Analogue Antineoplastic Agent in CLINICAL PHARMACOKINETICS
  • 1998-12 High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group in BRITISH JOURNAL OF CANCER
  • 1998-11 Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients in BRITISH JOURNAL OF CANCER
  • 1997-10 The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor in BRITISH JOURNAL OF CANCER
  • 1997-09 Matrix metalloproteinase inhibitors: Present achievements and future prospects in INVESTIGATIONAL NEW DRUGS
  • 1997-08 Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1997-06 A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1996-12 Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer in BRITISH JOURNAL OF CANCER
  • 1996-08 New promising anticancer agents in development: what comes next? in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1996-06 Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1996-05 Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer in BRITISH JOURNAL OF CANCER
  • 1996-03 Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration in BRITISH JOURNAL OF CANCER
  • 1996-02 Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group in BRITISH JOURNAL OF CANCER
  • 1996-02 Phase II clinical trials with rhizoxin in breast cancer and melanoma in BRITISH JOURNAL OF CANCER
  • 1996-01 Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.5645.2", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.10419.3d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.8993.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.48336.3a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417893.0", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.6906.9", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.154185.c", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.469474.c", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.476460.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417829.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5252.0", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.413532.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417993.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411414.5", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.410569.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.4494.d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417079.c", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.477947.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.267309.9", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.215654.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.443984.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417574.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.420044.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.436369.d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.240871.8", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.9909.9", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5284.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418116.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.419617.c", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.18886.3f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.8515.9", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.257127.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415720.5", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.14925.3b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.430814.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.424926.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.475435.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415193.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.9654.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418119.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5596.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.16872.3a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418936.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415978.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418019.5", 
            "type": "Organization"
          }
        ], 
        "familyName": "Verweij", 
        "givenName": "Jaap", 
        "id": "sg:person.01236641403.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236641403.86"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T14:49", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_558.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01236641403.86'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01236641403.86'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01236641403.86'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01236641403.86'


     

    This table displays all metadata directly associated to this object as RDF triples.

    104 TRIPLES      10 PREDICATES      55 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.01236641403.86 schema:affiliation N8505d146d5a9465f9c11f1124f649b63
    2 https://www.grid.ac/institutes/grid.10419.3d
    3 https://www.grid.ac/institutes/grid.14925.3b
    4 https://www.grid.ac/institutes/grid.154185.c
    5 https://www.grid.ac/institutes/grid.16872.3a
    6 https://www.grid.ac/institutes/grid.18886.3f
    7 https://www.grid.ac/institutes/grid.215654.1
    8 https://www.grid.ac/institutes/grid.240871.8
    9 https://www.grid.ac/institutes/grid.257127.4
    10 https://www.grid.ac/institutes/grid.267309.9
    11 https://www.grid.ac/institutes/grid.410569.f
    12 https://www.grid.ac/institutes/grid.411414.5
    13 https://www.grid.ac/institutes/grid.413532.2
    14 https://www.grid.ac/institutes/grid.415193.b
    15 https://www.grid.ac/institutes/grid.415720.5
    16 https://www.grid.ac/institutes/grid.415978.6
    17 https://www.grid.ac/institutes/grid.417079.c
    18 https://www.grid.ac/institutes/grid.417574.4
    19 https://www.grid.ac/institutes/grid.417829.1
    20 https://www.grid.ac/institutes/grid.417893.0
    21 https://www.grid.ac/institutes/grid.417993.1
    22 https://www.grid.ac/institutes/grid.418019.5
    23 https://www.grid.ac/institutes/grid.418116.b
    24 https://www.grid.ac/institutes/grid.418119.4
    25 https://www.grid.ac/institutes/grid.418936.1
    26 https://www.grid.ac/institutes/grid.419617.c
    27 https://www.grid.ac/institutes/grid.420044.6
    28 https://www.grid.ac/institutes/grid.424926.f
    29 https://www.grid.ac/institutes/grid.430814.a
    30 https://www.grid.ac/institutes/grid.436369.d
    31 https://www.grid.ac/institutes/grid.443984.6
    32 https://www.grid.ac/institutes/grid.4494.d
    33 https://www.grid.ac/institutes/grid.469474.c
    34 https://www.grid.ac/institutes/grid.475435.4
    35 https://www.grid.ac/institutes/grid.476460.7
    36 https://www.grid.ac/institutes/grid.477947.e
    37 https://www.grid.ac/institutes/grid.48336.3a
    38 https://www.grid.ac/institutes/grid.5252.0
    39 https://www.grid.ac/institutes/grid.5284.b
    40 https://www.grid.ac/institutes/grid.5596.f
    41 https://www.grid.ac/institutes/grid.6906.9
    42 https://www.grid.ac/institutes/grid.8515.9
    43 https://www.grid.ac/institutes/grid.8993.b
    44 https://www.grid.ac/institutes/grid.9654.e
    45 https://www.grid.ac/institutes/grid.9909.9
    46 schema:familyName Verweij
    47 schema:givenName Jaap
    48 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236641403.86
    49 schema:sdDatePublished 2019-03-07T14:49
    50 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    51 schema:sdPublisher N3820b2a16944494a92df3db2cc06fffd
    52 sgo:license sg:explorer/license/
    53 sgo:sdDataset persons
    54 rdf:type schema:Person
    55 N3820b2a16944494a92df3db2cc06fffd schema:name Springer Nature - SN SciGraph project
    56 rdf:type schema:Organization
    57 N8505d146d5a9465f9c11f1124f649b63 schema:affiliation https://www.grid.ac/institutes/grid.5645.2
    58 sgo:isCurrent true
    59 rdf:type schema:OrganizationRole
    60 https://www.grid.ac/institutes/grid.10419.3d schema:Organization
    61 https://www.grid.ac/institutes/grid.14925.3b schema:Organization
    62 https://www.grid.ac/institutes/grid.154185.c schema:Organization
    63 https://www.grid.ac/institutes/grid.16872.3a schema:Organization
    64 https://www.grid.ac/institutes/grid.18886.3f schema:Organization
    65 https://www.grid.ac/institutes/grid.215654.1 schema:Organization
    66 https://www.grid.ac/institutes/grid.240871.8 schema:Organization
    67 https://www.grid.ac/institutes/grid.257127.4 schema:Organization
    68 https://www.grid.ac/institutes/grid.267309.9 schema:Organization
    69 https://www.grid.ac/institutes/grid.410569.f schema:Organization
    70 https://www.grid.ac/institutes/grid.411414.5 schema:Organization
    71 https://www.grid.ac/institutes/grid.413532.2 schema:Organization
    72 https://www.grid.ac/institutes/grid.415193.b schema:Organization
    73 https://www.grid.ac/institutes/grid.415720.5 schema:Organization
    74 https://www.grid.ac/institutes/grid.415978.6 schema:Organization
    75 https://www.grid.ac/institutes/grid.417079.c schema:Organization
    76 https://www.grid.ac/institutes/grid.417574.4 schema:Organization
    77 https://www.grid.ac/institutes/grid.417829.1 schema:Organization
    78 https://www.grid.ac/institutes/grid.417893.0 schema:Organization
    79 https://www.grid.ac/institutes/grid.417993.1 schema:Organization
    80 https://www.grid.ac/institutes/grid.418019.5 schema:Organization
    81 https://www.grid.ac/institutes/grid.418116.b schema:Organization
    82 https://www.grid.ac/institutes/grid.418119.4 schema:Organization
    83 https://www.grid.ac/institutes/grid.418936.1 schema:Organization
    84 https://www.grid.ac/institutes/grid.419617.c schema:Organization
    85 https://www.grid.ac/institutes/grid.420044.6 schema:Organization
    86 https://www.grid.ac/institutes/grid.424926.f schema:Organization
    87 https://www.grid.ac/institutes/grid.430814.a schema:Organization
    88 https://www.grid.ac/institutes/grid.436369.d schema:Organization
    89 https://www.grid.ac/institutes/grid.443984.6 schema:Organization
    90 https://www.grid.ac/institutes/grid.4494.d schema:Organization
    91 https://www.grid.ac/institutes/grid.469474.c schema:Organization
    92 https://www.grid.ac/institutes/grid.475435.4 schema:Organization
    93 https://www.grid.ac/institutes/grid.476460.7 schema:Organization
    94 https://www.grid.ac/institutes/grid.477947.e schema:Organization
    95 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
    96 https://www.grid.ac/institutes/grid.5252.0 schema:Organization
    97 https://www.grid.ac/institutes/grid.5284.b schema:Organization
    98 https://www.grid.ac/institutes/grid.5596.f schema:Organization
    99 https://www.grid.ac/institutes/grid.5645.2 schema:Organization
    100 https://www.grid.ac/institutes/grid.6906.9 schema:Organization
    101 https://www.grid.ac/institutes/grid.8515.9 schema:Organization
    102 https://www.grid.ac/institutes/grid.8993.b schema:Organization
    103 https://www.grid.ac/institutes/grid.9654.e schema:Organization
    104 https://www.grid.ac/institutes/grid.9909.9 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...